scholarly journals In Vitro Activity of Monofunctional Pt-II Complex Based on 8-Aminoquinoline against Human Glioblastoma

Pharmaceutics ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2101
Author(s):  
Valentina Coccè ◽  
Isabella Rimoldi ◽  
Giorgio Facchetti ◽  
Emilio Ciusani ◽  
Giulio Alessandri ◽  
...  

A new cationic Pt(II) complex bearing 8-aminoquinoline as chelating ligand (called Pt-8AQ) was evaluated against two human carcinomas, one mesothelioma, and three glioblastoma cell lines. The in vitro comparison to the clinically approved CisPt showed a minor activity of Pt-8AQ against carcinoma and mesothelioma, whereas a significant activity of Pt-8AQ was observed on the proliferation of the three glioblastoma cell lines (U87-MG IC50 = 3.68 ± 0.69 µM; U373-MG IC50 = 11.53 ± 0.16 µM; U138-MG IC50 = 8.05 ± 0.23 µM) that was higher than that observed with the clinically approved CisPt (U87-MG IC50 = 7.27 + 1.80 µM; U373-MG IC50 = 22.69 ± 0.05 µM; U138-MG IC50 = 32.1 ± 4.44 µM). Cell cycle analysis proved that Pt-8AQ significantly affected the cell cycle pattern by increasing the apoptotic cells represented by the sub G0/G1 region related with a downregulation of p53 and Bcl-2. Moreover, an NMR investigation of Pt-8AQ interaction with 9-EtG, GSH, and Mets7 excluded DNA as the main target, suggesting a novel mechanism of action. Our study demonstrated the high stability of Pt-8AQ after incubation at 37 °C and a significant antineoplastic activity on glioblastomas. These features also make Pt-8AQ a good candidate for developing a new selective advanced cell chemotherapy approach in combination with MSCs.

2012 ◽  
Vol 131 (2) ◽  
pp. E33-E44 ◽  
Author(s):  
Pietro Ferruzzi ◽  
Federica Mennillo ◽  
Antonella De Rosa ◽  
Cinzia Giordano ◽  
Marco Rossi ◽  
...  

Oncology ◽  
2003 ◽  
Vol 64 (4) ◽  
pp. 459-467 ◽  
Author(s):  
Isabelle Pommepuy ◽  
Faraj Terro ◽  
Barbara Petit ◽  
Frank Trimoreau ◽  
Virginie Bellet ◽  
...  

2002 ◽  
Vol 50 (6) ◽  
pp. 479-489 ◽  
Author(s):  
Ioannis A. Avramis ◽  
Garyfallia Christodoulopoulos ◽  
Atsushi Suzuki ◽  
Walter E. Laug ◽  
Ignacio Gonzalez-Gomez ◽  
...  

2002 ◽  
Vol 160 (4) ◽  
pp. 1279-1292 ◽  
Author(s):  
L'Houcine Ouafik ◽  
Samantha Sauze ◽  
Françoise Boudouresque ◽  
Olivier Chinot ◽  
Christine Delfino ◽  
...  

1989 ◽  
Vol 12 (4) ◽  
pp. 169-174 ◽  
Author(s):  
H. Fischer ◽  
W.J. Zeller ◽  
K. Schwechheimer ◽  
K.-J. Hutter ◽  
B. Wowra ◽  
...  

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e13560-e13560
Author(s):  
Dorothee Gramatzki ◽  
Emese Szabo ◽  
Martin Gramatzki ◽  
Matthias Peipp ◽  
Michael Weller

e13560 Background: Glioblastoma is the most common primary malignant brain tumor with a poor prognosis. CD317 (HM1.24) is a transmembrane protein and may exist in differently spliced variants. It is highly expressed on plasma cells in multiple myeloma, as well as in certain solid tumor types. While several antibody drug conjugates are already in clinical practice, small immunotoxins with a different intracellular mode of action are only established in hairy cell leukemia. The immunotoxin HM1.24-ETA’ protein is a CD317 single chain Fv (scFv) antibody fused to a truncated version of Pseudomonas aeruginosa exotoxin A (ETA’). Methods: In vivo CD317 mRNA expression in human glioma of different grades and survival probabilities of glioblastoma patients based on CD317 mRNA expression were analyzed using the database of the Cancer Genome Atlas network (TCGA). CD317 protein expression was analyzed by immunohistochemistry in a human tissue microarray (TMA). In vitro CD317 mRNA expression was assessed by RT-PCR and CD317 protein levels by flow cytometry in several human glioblastoma cell lines. A cytotoxicity assay after treatment with HM1.24-ETA’ immunotoxin was performed in human glioblastoma cell lines. Results: Data on mRNA expression from the TCGA database demonstrated, that CD317 was upregulated in human glioblastomas compared to lower grade gliomas. In the group of glioblastoma patients increased CD317 mRNA expression was associated with decreased probability of survival ( p< 0.001). CD317 protein levels correlated directly with the tumor grade of astrocytic gliomas in the TMA. CD317 was expressed heterogeneously on mRNA and protein levels in the tested cell-lines in vitro. HM1.24-ETA’ induced cytotoxicity in CD317-positive glioblastoma cells in a concentration-dependent manner. Animal experiments currently performed suggest activity in glioblastoma xenografted mice. Conclusions: These data highlight CD317 as an interesting target antigen and HM1.24-ETA’ immunotoxin as a strategy for immunotherapy of glioblastoma patients.


Sign in / Sign up

Export Citation Format

Share Document